Brokers Set Expectations for Immatics FY2026 Earnings

Key Points

• Chardan Capital forecasts Immatics will report earnings of ($1.53) per share for FY2026, significantly lower than the current consensus estimate of ($0.72) per share.
• Immatics' stock has received mixed ratings, with a consensus rating of "Moderate Buy" and a price target of $13.67 as evaluated by various analysts.
• Recent institutional activity includes significant increases in holdings by Bank of America and Mitsubishi UFJ Asset Management, reflecting growing interest from hedge funds.

Immatics N.V. (NASDAQ:IMTX - Free Report) - Equities research analysts at Chardan Capital issued their FY2026 EPS estimates for Immatics in a research note issued to investors on Monday, October 13th. Chardan Capital analyst Y. Livshits forecasts that the company will post earnings of ($1.53) per share for the year. The consensus estimate for Immatics' current full-year earnings is ($0.72) per share.

Several other equities analysts have also recently weighed in on the company. Guggenheim assumed coverage on Immatics in a research note on Thursday, September 18th. They set a "buy" rating and a $16.00 target price on the stock. Zacks Research upgraded Immatics from a "strong sell" rating to a "hold" rating in a report on Monday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Immatics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immatics presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.67.

Immatics Trading Up 0.8%

IMTX stock opened at $10.17 on Wednesday. The company has a market capitalization of $1.24 billion, a P/E ratio of -15.65 and a beta of 1.22. The firm has a 50 day simple moving average of $6.87 and a 200-day simple moving average of $5.82. Immatics has a twelve month low of $3.30 and a twelve month high of $10.95.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.28). The company had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%.

Hedge Funds Weigh In On Immatics

A number of institutional investors and hedge funds have recently modified their holdings of IMTX. Bank of America Corp DE increased its holdings in shares of Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after purchasing an additional 2,231 shares during the last quarter. Pale Fire Capital SE boosted its stake in shares of Immatics by 8.9% during the 1st quarter. Pale Fire Capital SE now owns 34,270 shares of the company's stock worth $155,000 after acquiring an additional 2,808 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Immatics by 28.7% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company's stock worth $172,000 after buying an additional 7,116 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Immatics in the 2nd quarter worth approximately $59,000. Finally, Algert Global LLC lifted its holdings in Immatics by 20.6% in the first quarter. Algert Global LLC now owns 70,668 shares of the company's stock valued at $319,000 after acquiring an additional 12,072 shares during the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.